A corporate VC — the venture arm of a large medical device, diagnostics, or health system company — brings distribution, regulatory credibility, and a possible acquirer to your cap table. It also brings constraints on exit optionality, information rights that leak to a competitor, and board dynamics that can slow pivots. Take one when their strategic value clearly exceeds the optionality cost, and never earlier than Series A.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • Corporate venture capital (CVC) is venture investment made by the strategic arm of a large operating company — in MedTech, typically a device maker, diagnostics group, pharma company, or hospital network.
  • CVCs bring three real advantages over pure financial VCs: distribution channel access, regulatory and clinical credibility with notified bodies and hospitals, and a warm signal to future acquirers.
  • CVCs also impose three real costs: signalling and right-of-first-refusal clauses that narrow your exit universe, information rights that can leak competitive intel, and board members whose loyalty to the parent overrides the startup's independent interest.
  • The MDR does not care who is on your cap table — but your investors influence how fast you can execute the regulatory work, because they control the runway that funds your QMS, clinical data, and notified body fees.
  • A sensible default: no corporate money at pre-seed or seed, selective strategic participation at Series A (minority, standard terms, no special rights), and only then consider larger strategic commitments at Series B+.

Why this matters

Most European MedTech founders meet a corporate VC before they have thought through what a corporate VC actually is. A friendly introduction lands in the inbox — the innovation team at a large orthopaedics company, the digital health fund of a hospital group, the strategic arm of a diagnostics multinational. The deck looks the same as any other VC. The conversation sounds similar. And the cheque is real.

The difference only becomes visible eighteen months later, when you want to raise from a competitor of the strategic on your cap table, or when a different acquirer wants to buy you and discovers a right of first refusal buried in the side letter.

Strategic investors are not wrong. For many MedTech companies they are the single most valuable line on the cap table. But the decision to take strategic money has second-order consequences that a pure financial VC round does not carry, and those consequences interact with your MDR path in ways that deserve clear thinking before you sign a term sheet.

What MDR actually says (and doesn't)

The MDR is silent on who owns your company. Regulation (EU) 2017/745 addresses manufacturers, authorised representatives, importers, distributors, and notified bodies. It does not mention investors, boards, or shareholder agreements.

What MDR does require is that the legal manufacturer — the entity whose name goes on the label under Article 10 and Article 20 — holds the obligations for the QMS, technical documentation, post-market surveillance, and vigilance. A change of control does not automatically change the manufacturer. But a change of manufacturer (for example, if a strategic acquirer wants the device under their own CE certificate) triggers a new conformity assessment, a new Basic UDI-DI, and notified body review under Annex IX.

This matters for strategic investors because some of them will push — directly or subtly — toward an integration path where their parent company eventually becomes the manufacturer. That is a regulatory event, not just a commercial one. It takes months and money. If the strategic relationship assumes an eventual absorption into the parent's portfolio, the cost of that transition belongs in the conversation from day one.

The manufacturer definition in Article 2(30), the QMS obligation in Article 10(9), and the Person Responsible for Regulatory Compliance requirement in Article 15 all follow the legal entity. None of them transfer automatically on acquisition.

A worked example

A Series A surgical robotics startup in Munich has raised EUR 8 million from two financial VCs. A Class IIb device is eighteen months from CE marking. The strategic arm of a large orthopaedics multinational — call them OrthoCo — offers EUR 4 million at a 20 percent premium to the next round's expected valuation, with three conditions:

  1. A board observer seat.
  2. A right of first negotiation on any acquisition offer.
  3. A commercial agreement giving OrthoCo's European sales force the right to distribute the device in six countries after CE marking.

The founders calculate: the premium valuation avoids dilution, the distribution agreement is worth potentially EUR 20 million in revenue over three years, and the board observer is non-voting.

What they miss on the first pass: the right of first negotiation means that every future strategic bidder will know OrthoCo gets to match. That depresses competing offers. At exit, a 15 percent discount on bid price is realistic, and on an expected EUR 150 million sale that is EUR 22.5 million lost — more than the entire investment brought in.

The distribution agreement is real but also locks the device into OrthoCo's channel economics. If OrthoCo later decides to prioritise a competing product from their own R&D, the startup has ceded commercial control in six countries with no easy path to rebuild direct sales.

The founders end up negotiating: they accept the investment at standard terms, drop the right of first negotiation, convert the distribution agreement to a non-exclusive co-promotion, and keep the observer seat. OrthoCo agrees because the startup is strong. A weaker startup would not have that leverage.

The lesson is not that the deal was bad. It is that strategic money requires a different negotiation than financial money, and the founder has to know which terms matter.

The Subtract to Ship playbook

Strategic capital is one of those decisions where adding the wrong thing is worse than adding nothing. The subtract-to-ship approach: only accept what you cannot get elsewhere, and only pay the price you can clearly justify.

1. Name what the strategic actually brings. Write down, in one page, the three to five things this specific strategic can provide that a financial VC cannot. Distribution access in which countries, with which sales force, under which commercial terms. Regulatory credibility with which notified body. Clinical site access at which hospitals. Access to which key opinion leaders. If the list is generic — "brand credibility," "industry expertise" — the strategic value is not real. Walk away.

2. Price the optionality you are giving up. Every special right a strategic asks for has a price in future exit optionality. A right of first refusal, a right of first negotiation, an information right that includes competitive data, a board seat tied to parent company employment — each one narrows your future choices. Estimate that narrowing in percentage terms and in euros at your expected exit. If the strategic's contribution does not clearly exceed the optionality cost, the deal is bad even if the valuation is high.

3. Take strategic money as minority, not as lead, at least until Series B. A financial VC leading your round with a strategic participating as a minority keeps the governance clean. The lead investor's incentives are aligned with maximising exit value. The strategic's incentives are aligned with their parent company's portfolio. When the strategic leads, those misaligned incentives sit at the head of the table. Avoid that arrangement until you have enough leverage to negotiate carve-outs.

4. Do not let a strategic fund your pre-seed or seed. At the earliest stages you need flexibility — to pivot intended purpose, to change classification strategy, to pick a different notified body, to change the entire business model. A strategic on the cap table at pre-seed has disproportionate influence on a company where decisions are still being made hour by hour. Save strategic capital for Series A, when the product and the regulatory path are clear enough that the strategic can provide targeted help rather than general interference.

5. Match strategic capital to a specific regulatory milestone. The best use of strategic money is to fund a specific, well-defined regulatory or commercial milestone: notified body submission, clinical investigation completion, first market launch. The strategic's strategic value peaks at that milestone, and the alignment is clearest. Open-ended strategic investment where the money funds general runway creates open-ended strategic influence.

6. Protect your manufacturer identity. Never agree to terms that would transfer the MDR manufacturer role to the strategic parent without a specific, negotiated process. Your CE certificate, your technical documentation, your notified body relationship — these belong to the legal manufacturer under Article 10. If an exit later involves absorbing the device into the strategic's portfolio, that is a regulatory project in its own right, budgeted and planned like any other project. Do not let vague integration language commit you to something that will cost you six months and several hundred thousand euros to execute.

7. Read the information rights carefully. Financial VCs get standard information rights — financial reporting, board materials, major decisions. Strategics sometimes ask for more: access to clinical data, technical file summaries, commercial pipeline details. Every additional information right is a potential leak channel to the parent company's competing products. Default to standard VC information rights unless there is a specific, narrow reason to expand them.

8. Build an exit thesis before the strategic joins. Write down, before signing, what your expected exit universe looks like: which companies are realistic acquirers, which IPO paths are plausible, which timelines are realistic. Then overlay the strategic's constraints on that universe. If the strategic eliminates more than one serious acquirer from the picture, the deal is likely too expensive.

Reality Check

  • Can you name, in one sentence, the specific strategic contribution this investor brings that no financial VC could match?
  • Have you priced the optionality cost of their special rights (ROFR, ROFN, board seat, information rights) in euros at your expected exit?
  • Do you have a financial VC leading the round, with the strategic as a minority participant?
  • Does your term sheet avoid any language that commits to transferring the MDR manufacturer role to the strategic parent?
  • Are you past Series A, with a clear regulatory path and a defined intended purpose that will not pivot?
  • Have you mapped your expected acquirer universe and confirmed that the strategic does not eliminate more than one serious bidder?
  • Is the strategic capital tied to a specific regulatory or commercial milestone rather than funding general runway?
  • Have your existing financial investors signed off on the strategic's participation after reviewing the full term sheet?

Frequently Asked Questions

Is corporate VC money "dumber" than financial VC money? No. Corporate VCs can be excellent investors with genuine operating experience. The difference is not intelligence — it is incentive alignment. A financial VC wants the highest exit price. A corporate VC wants that plus strategic benefit to the parent. Those goals often align, but when they diverge the corporate VC's vote goes to the parent.

Can we take strategic money at seed stage? Rarely wise. At seed you are still shaping intended purpose, classification, and business model. Strategic influence on those decisions — even well-meaning — can lock you into paths that fit the parent's portfolio rather than your best market. If a strategic insists on seed participation, take a small amount with no special rights and treat it as a grant.

Does having a corporate VC help with notified body selection? Not directly. Notified bodies operate independently and do not favour devices from companies backed by specific investors. What can help is the operating experience the corporate VC brings — people who have been through audits, who know what a good technical file looks like, who can introduce you to experienced consultants. The benefit is know-how, not influence.

Should we take money from a direct competitor's venture arm? Almost never. Even with information walls and legal protections, the reputational and competitive risk is significant. Competing companies will hear about it and factor it into their own acquisition decisions later. Strategic investment from an adjacent company — a hospital system, a diagnostics player, a distribution partner — carries far less baggage.

How do we exit a strategic investor if the relationship sours? This is why side letters matter. Before accepting strategic capital, negotiate explicit termination rights for the commercial side of the relationship (distribution agreements, co-development agreements) separate from the equity investment. Equity is permanent until an exit; commercial relationships should have clear exit clauses so that a failed partnership does not paralyse the company.

Does the MDR care who our investors are? No. The MDR regulates manufacturers, not cap tables. But investors influence how fast you execute the regulatory work, because they control the runway. A strategic investor who understands MDR timelines is easier to work with than a financial VC who expects SaaS-speed growth.

Sources

  1. Regulation (EU) 2017/745 on medical devices, consolidated text. Articles 10, 15, 20, and 120.
  2. EN ISO 13485:2016+A11:2021 — Quality management systems for medical devices.